Navigation Links
FASgen Announces Significant Milestone in Its Cancer Drug Development Program
Date:10/1/2007

BALTIMORE, Oct. 1 /PRNewswire/ -- FASgen's fatty acid synthase inhibitor (FASi) compounds, led by FAS031, have demonstrated efficacy against every solid tumor xenograft cell line tested, in both orthotopic and flank models: 4 lung tumor cell lines (H460; A549; H1975; LX7); two ovarian; breast; and, colon. In many cases the tumors were eradicated entirely. The compounds have been shown in extensive preclinical studies to be remarkably safe and orally available. One compound was safely given to mice twice a day orally for 6 months with no observed adverse side effects except the elimination of the tumors. Other compounds were given to mice in a two year experiment and prevented the onset of tumors in nearly one-third of the mice. That experiment was repeated with a different compound and produced the same result. Several of these results have been recently published and others will shortly be published in leading oncology journals.

FASi is a new mechanism of action for the treatment of cancer. The fatty acid biosynthesis pathway is critical to all living organisms to produce fat and regulate the body's energy. In cancer cells, FASgen researchers over the last 15 years have discovered that the mechanism acts differently. As cancer cells do not produce fat, the fatty acid biosynthesis pathway in the transformed cell acts to regulate the energy source that keeps the cell alive. One critical enzyme in that pathway is FAS. The Company's researchers have discovered that inhibition of FAS kills the cancer cell, a result that has been recently replicated in a number of labs and become the subject of a series of new publications. FASgen has developed a library of FASi compounds and has an extensive body of intellectual property surrounding both the mechanism of action and uses for the compounds, and of course the composition of individual compounds. "This discovery holds out the prospect for a new method of treatment for cancer that is remarkably safe and may dimi
'/>"/>

SOURCE FASgen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)..., , ABBOTT PARK, Ill., Nov. 19 /PRNewswir...Abbott (NYSE: ABT ) as one of its Most Admired C...r. The Deal honored Abbott as its Most Admired ... strategic use of acquisitions and divestitures si...tt has reshaped its business portfolio with a focu...
(Date:11/19/2009)..., , Part of International Internet Wee...Newswire-USNewswire/ -- The U.S. Food and Drug Adm...g, international effort, called the International ...llegal actions involving medical products. ,, (...4/FDALOGO ) ,, During the effort, the FDA,s Off...
(Date:11/19/2009)..., , PRINCETON, N.J., Nov. 19 /PRNewswire...paring alternatives to traditional spinal fusion s...on to its executive management team as the Vice Pr..., (Logo: http://www.newscom.com/cgi-bin/prnh/20...ears of clinical and regulatory experience in the ...
Breaking Medicine Technology:The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2Impliant Announces the Addition of Vice President of Clinical and Regulatory Affairs to Executive Management Team 2Impliant Announces the Addition of Vice President of Clinical and Regulatory Affairs to Executive Management Team 3Glencoe Software to Support the ASCB Stimulus Grant to Build Virtual Image Library of the Cell 10625 1Glencoe Software to Support the ASCB Stimulus Grant to Build Virtual Image Library of the Cell 10625 2Milwaukee County Employees Retirement System 28MCERS 29 Goes Live with V3 Self Service 60668 1Milwaukee County Employees Retirement System 28MCERS 29 Goes Live with V3 Self Service 60668 2RNL BIO Rescues a College Student from Autoimmune Hearing Loss 14716 1RNL BIO Rescues a College Student from Autoimmune Hearing Loss 14716 2RNL BIO Rescues a College Student from Autoimmune Hearing Loss 14716 3RNL BIO Rescues a College Student from Autoimmune Hearing Loss 14716 4
...owered Blood Glucose without Pr...ed to Begin upon Ethics Approval with Results due ...OURNE, Australia, Aug. 8 Phosphagenics,Limited ("... today,announced the successful completion of a Ph...ults of the trial demonstrated the ability of the,...
...tion,(Nasdaq: IOMI ) today announced that interim...trial of its patch-based vaccine for travelers, di...ccine -- 19 elderly and 17 adult,participants -- m... elderly,subjects with weaker immune systems respo...are the number of elderly subjects (65,and older) ...
Other Medicine Technology:Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results 2Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results 3Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers' Diarrhea Patch Vaccine 2Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers' Diarrhea Patch Vaccine 3Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers' Diarrhea Patch Vaccine 4
(Date:11/22/2009)...ov. 21 Congressman Chak...n the United States Senate,s vote tonight to proce...: ,, "Senators Arlen Specter and Bob Casey dese...nians for casting stand-up, critical votes in the ...c Affordable Health Care Reform legislation to ful...
(Date:11/21/2009)... Nov. 21 DNC Chairman T...Senate voted to begin full debate of health insura...newscom.com/cgi-bin/prnh/20080519/DNCLOGO ) ,... the road to enacting health insurance reform. By ...ll now have an opportunity to debate the health re...
(Date:11/21/2009)...ov. 21 Milvia Lopez, by her attorn...ntly filed suit, in Supreme Court, New York County...es that while Ms. Lopez underwent a routine transe... HOSPITAL , doctors used an HIV infected scope exp...at several hours after being discharged from the p...
(Date:11/21/2009)...n Discusses Key Provisions of Legislation, Continu...ST. CHARLES, Ill., Nov. 21 /PRNewswire-USNewswire/...ng the landmark Affordable Health Care for America... reform legislation forward, Congress has taken de...e system. Today, AARP hosted an educational forum...
(Date:11/21/2009)... NH based medical credentialing software company... form a partnerhsip with Amerinet, Inc., the leadi... will help to transform quality care within the he...) November 21, 2009 -- ISG Group, LLC, doing busin...ement with Amerinet Inc., a leading national healt...
Breaking Medicine News(10 mins):Health News:Democratic National Committee Chairman Tim Kaine's Statement on the Senate's Vote to Proceed to Full Floor Debate of Health Insurance Reform Legislation 2Health News:Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure 2Health News:AARP Hosts Rep. Bill Foster In Health Care Reform Forum 2Health News:IntelliSoft Group and Amerinet Inc. Form Partnership to Transform Healthcare Delivery of Quality Patient Safety and Care 2
...dates on the impact of,climate changes on insect-b...the importance of childhood immunizations were pre...Press Club in Washington, D.C. The news,conference...due to drug resistant bacteria., "Infectious dise...
...und what they believe to be the most accurate way ...he growing number of obese mothers, according to a...etrics and Gynecology . , Experts from the Univer...station-adjusted projection method (GAP). , The ...
...macy Directors Will Move Razadyne and Razadyne ER,...nched, According to a New Repo...9 Decision Resources, one of the,world,s leading ...lantamine) in December 2008 will,have the greatest...
... Nyer Medical Group,Inc. (Nasdaq: NYER ) announce...., ("ADCO South") its Florida Medical-Surgical div...vision, D.A.W. Inc., was awarded a two-year,contra...award was made at the conclusion of a competitive,...
... to its unparalleled content on breastfeeding with...essional articles on child, health, from allergies...., BOULDER, Colo., July 9 Breastfeeding.com, a p...fessional articles on infant, toddler, and child h...
... Licensed-Rx, one of the leading online pharma...tee customers up to 10% off all new orders placed....9, 2008 -- Licensed RX has announced its latest cu...1985060323) was released and is valid for the firs...
Other Medicine News:Health News:Public Health Experts Provide Update on Current Infectious Diseases Threats 2Health News:Public Health Experts Provide Update on Current Infectious Diseases Threats 3Health News:Research highlights problems of predicting birthweights in obese mothers 2Health News:Research highlights problems of predicting birthweights in obese mothers 3Health News:Primary Care Physicians' Prescriptions of Aricept for Alzheimer's Disease Will Drop by 20 Percent Following the Availability of Generic Razadyne in December 2008 2Health News:Primary Care Physicians' Prescriptions of Aricept for Alzheimer's Disease Will Drop by 20 Percent Following the Availability of Generic Razadyne in December 2008 3Health News:Nyer Medical Group, Inc. Announces Sale of Company's Florida Medical-Surgical Division; Pharmacy Division Awarded Two-Year Preferred Supplier Contract 2Health News:Nyer Medical Group, Inc. Announces Sale of Company's Florida Medical-Surgical Division; Pharmacy Division Awarded Two-Year Preferred Supplier Contract 3Health News:Breastfeeding.com Becomes a Premier Resource on Child Health 2
SureStep AMPII/BZO300/COC/MDMA/MOP/THC
SureStep THC/COC/MAMPII
SureStep THC/COC
SureStep Barbiturates (BAR)
Medicine Products: